Fermenta Biotech Ltd · NSE:FERMENTA
Fermenta Biotech — H1 FY2027 Earnings Presentation
19 slides from Fermenta Biotech's earnings presentation, Nov 6, 2026
Slide 1: Intimation of Earnings Presentation Q2/H1FY27 cover letter
November 06, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, Fort, G Block, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai 400 051 Scrip Code: 506414 Trading Symbol: FERMENTA Dear Sir, Sub.: Intimation o
Slide 2: Q2/H1FY27 presentation
Fermenta Biotech Ltd Q2/H1FY27 presentation 06 November 2026
Slide 3: Disclaimer
Disclaimer By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited (“FBL”) nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on t
Slide 4: Innovation Chemistry for Global Nutrition & Wellness
Innovation Chemistry for Global Nutrition & Wellness As preventive healthcare awareness rises, global demand is accelerating for science-backed, top-quality nutritional ingredients. Fermenta pairs process and molecular expertise with science-validated capability to deliver best-in-class ingredients,
Slide 5: Q2/H1FY27 Highlights
Q2/H1FY27 Highlights Financials (consolidated) Performance Q2FY27 H1FY27 • Q2 revenue up 8% on Q1 to INR 135.8 crore, level with Q2FY26; EBITDA up 3% on Q1 INR 135.8 crore INR 261.9 crore Revenue (up 0.1% YoY, up 8% QoQ) (down 7% YoY) • Human Nutrition grew 2% in H1 to INR 162.5 crore, with volumes
Slide 6: Lines of Business
Lines of Business Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 - Human Vitamin D3 - Animal Others Premium supplements, food Specialized formulations for Customized Food Premixes, fortification, and pharmaceuticals livestock and pou
Slide 7: Revenue Mix (Consolidated)
Revenue Mix (Consolidated) Human Nutrition rises to 62% of revenue as animal nutrition prices reset (₹ Crore) 9% 5% 6% 5% 6% FY25 FY26 H1FY26 H1FY27 9% 9% 5% 8% Nutrition Business 350 435 220 2 09 8% 6% 5% 9% 8% Vitamin D3 - Human Nutrition 228 293 159 163 20% 16% 8% Vitamin D3 - Animal Nutrition 82
Slide 8: Diversified Markets, Balanced Customers
Diversified Markets, Balanced Customers India rises to half of revenue, and customer concentration stays low Customer profile, H1FY27 Geographical revenue mix Excluding value unlocking Revenue from largest customer 9% H1FY27 51% 21% 9% 18% Revenue from top 5 customers 28% Revenue from top 10 custome
Slide 9: Financials: H1FY27 Cash Generation Strengthens
Financials H1FY27: Cash Generation Strengthens as Earnings Absorb a Price Reset Income Statement (₹ Crore) Balance Sheet (₹ Crore) Cash Flow (₹ Crore) Total income fell 7% and profit before tax Cash rose 11% to INR 102 crore and debt Operating cash flow rose 44% on a 45%, as animal nutrition prices
Slide 10: Ratios
Ratios Lower Leverage | Comfortable Liquidity | Returns Reset with Earnings FY24 FY25 FY26 H1FY27* LIQUIDITY ▪ EBITDA margin 17.9%, from 23.3% in FY26, as animal Current 1.4 1.58 1.86 1.69 nutrition prices fell Quick 0.8 0.87 0.99 0.90 ASSET MANAGEMENT ▪ ROE 9.2% and ROA 5.6%, annualised, in line wi
Slide 11: Cost Breakdown (% of Revenue) w/o Real Estate
Cost Breakdown (% of Revenue)—w/o Real Estate Material Costs Steady; Fixed Costs Weigh on a Lower Revenue Base Cost Components H1FY26 H1FY27 Change Key Drivers Raw Materials 36.98% 37.29% +31 bps Material cost share steady Employee Cost 15.20% 18.38% +318 bps Employee costs up 15% on a lower revenue
Slide 12: The Opportunity
The Opportunity Unlocking growth: Fermenta’s unique position to meet evolving health and nutrition demands worldwide India Global Innovation Drivers ✓ Preventive health ✓ Nutritional supplements ✓ Plant-source actives awareness ✓ Ageing drives vitamin D ✓ Biocatalysis & green chemistry ✓ Growing mid
Slide 13: Fermenta's Core Proposition
Fermenta’s Core Proposition Society Advance global health and preventive care through science-validated ingredients and actives Support life and productivity across human and animal populations Address environmental challenges through green chemistry and sustainable processes Best-in-class, science-
Slide 14: Manufacturing and R&D
Manufacturing and R&D Enzymes and APIs including Vitamin D3 Customized premix plant Kullu Multiple global regulatory certifications Dedicated Vitamin D3 with Himachal Pradesh backward integration for cholesterol Collaboration with toll manufacturer for Vitamin Multiple global regulatory Dahej D3 500
Slide 15: VITADEE Green Wins FSSAI Approval
VITADEE Green® Wins FSSAI Approval Plant-source Vitamin D3 (Cholecalciferol) cleared in July 2026 for use in health supplements, nutraceuticals and food products ® From patent to market 2024 Plant-source D3 technology transferred from R&D to manufacturing What it is • Vitamin D3 derived from plant s
Slide 16: Strategic Partnership Ecosystem
Strategic Partnership Ecosystem The Collaboration Strategic Value Global healthcare company Vitamin D awareness campaigns Extends our reach to healthcare specializing in diagnostics, Print and audiovisual educational materials professionals and patients medical devices, and nutrition Premier food te
Slide 17: R&D Focus Areas & Achievements
R&D Focus Areas & Achievements Focus Key Achievements Future Directions Calcifediol commercialization API Product pipelines Commercialized 11 products including Cholesterol, Lanolin derivatives VITADEE Green® Process improvement Enhanced Phenyramidol HCl process VITADEE SD (Spray Dried) Yield enhanc
Slide 18: Strategic Portfolio for Future Growth
Strategic Portfolio for Future Growth f Spray-Dried Vitamin D3 VITADEE Green® Calcifediol Customized Premixes ✓ Patented 100,000 IU/g ✓ Plant-based Vitamin D3 with ✓ Next-generation Vitamin D ✓ Equipped with advanced instrumentation pharmaceutical-grade technology clean-label for vegan supplement me
Slide 19: Thank you
Thank you Sumesh Gandhi - CFO sumesh.gandhi@fermentabiotech.com Fermenta Biotech Ltd